Biotechs Continue to Underperform (IBB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
Leerink Partners Reiterates Outperform on BioMarin Pharma (BMRN) Following Mixed Ph. 3 Data Results
March 21, 2016 1:17 PM EDTLeerink Partners reiterated an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's mixed PEG-PAL Ph. 3 data. In study '302, blood Phe elevated to near-baseline levels (1385.7 uM) upon discontinuation vs. pts. continuing PEG-PAL treatment (527.2 uM) (p... More
Leerink Partners Cuts Price Target on Alexion Pharma (ALXN) to $216; Reiterates Outperform
March 18, 2016 6:48 AM EDTLeerink Partners maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $216.00 (from $217.00). Conviction about the company is based on a positive outlook for Soliris [aHUS, PNH] and its potential in existing and new indications, as well as... More
